Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 2, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 4, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0002163153-26-000002
Filed / recorded
Nov 4, 2026, 12:23 PM UTC
Added to OQRO
Nov 4, 2026, 12:25 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Estrella Immunopharma, Inc.
Issuer CIK
1844417
Ticker
ESLA
Reporting person
Cynthia Pussinen
Relationship
Director, Officer
Officer title
Chief Executive Officer
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Nov 2, 2026
Transaction code
A
Shares / units
1,000,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
1,000,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
The option was granted under the Issuer's 2023 Omnibus Incentive Plan and was approved in advance by the Compensation Committee of the Board of Directors and the Board of Directors in accordance with Rule 16b-3(d).
The option vests and becomes exercisable as to 25% of the underlying shares on October 25, 2027 and as to the remaining 75% in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer through each vesting date.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.